ArticleClinical and experimental immunology2014
Ex-vivo tolerogenic F4/80⁺ antigen-presenting cells (APC) induce efferent CD8⁺ regulatory T cell-dependent suppression of experimental autoimmune uveitis.
Article in Clinical and experimental immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Ocular Microbiota and Intraocular Inflammation.Frontiers in immunology · 2020Pooled it
- Ocular immune homeostasis-mechanisms of precise regulation through coordination of the eye, visual system and beyond: a narrative review.Annals of eye science · 2026Article
- Ocular immune privilege in action: The living eye imposes unique regulatory and anergic gene signatures on uveitogenic T cells.Cell reports · 2025Article
- Innate immune cellular therapeutics in transplantation.Frontiers in transplantation · 2023Article
- Enhancement of the Tolerogenic Phenotype in the Liver by ImmTOR Nanoparticles.Frontiers in immunology · 2021Article
- Suppression of the Reactive Oxygen Response Alleviates Experimental Autoimmune Uveitis in Mice.International journal of molecular sciences · 2020Article
- Tolerogenic dendritic cells in organ transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2020Review
- Progress in Liver Transplant Tolerance and Tolerance-Inducing Cellular Therapies.Frontiers in immunology · 2020Review
- The Neuropeptides of Ocular Immune Privilege, α-MSH and NPY, Suppress Phagosome Maturation in Macrophages.ImmunoHorizons · 2018Article
- Generation, Characteristics and Clinical Trials of Ex Vivo Generated Tolerogenic Dendritic Cells.Yonsei medical journal · 2018Review
- Re-programming immunosurveillance in persistent non-infectious ocular inflammation.Progress in retinal and eye research · 2018Review
- Negative regulators that mediate ocular immune privilege.Journal of leukocyte biology · 2018Review
- Immune Privilege and Eye-Derived T-Regulatory Cells.Journal of immunology research · 2018Review
- Cellular and Molecular Mechanisms of Anterior Chamber-Associated Immune Deviation (ACAID): What We Have Learned from Knockout Mice.Frontiers in immunology · 2017Review
- Ocular Immune Privilege and Transplantation.Frontiers in immunology · 2016Review
- Cell therapy for immunosuppression after kidney transplantation.Langenbeck's archives of surgery · 2015Review
- Macrophages and Uveitis in Experimental Animal Models.Mediators of inflammation · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
It is known that inoculation of antigen into the anterior chamber (a.c.) of a mouse eye induces a.c.-associated immune deviation (ACAID), which is mediated in part by antigen-specific local and peripheral tolerance to the inciting antigen. ACAID can also be induced in vivo by intravenous (i.v.) inoculation of ex-vivo-generated tolerogenic antigen-presenting cells (TolAPC). The purpose of this study was to test if in-vitro-generated retinal antigen-pulsed TolAPC suppressed established experimental autoimmune uveitis (EAU). Retinal antigen-pulsed TolAPC were injected i.v. into mice 7 days post-induction of EAU. We observed that retinal antigen-pulsed TolAPC suppressed the incidence and severity of the clinical expression of EAU and reduced the expression of associated inflammatory cytokines. Moreover, extract of whole retina efficiently replaced interphotoreceptor retinoid-binding protein (IRBP) in the preparation of TolAPC used to induce tolerance in EAU mice. Finally, the suppression of EAU could be transferred to a new set of EAU mice with CD8⁺ but not with CD4⁺ regulatory T cells (T(reg)). Retinal antigen-pulsed TolAPC suppressed ongoing EAU by inducing CD8⁺ T(reg) cells that, in turn, suppressed the effector activity of the IRBP-specific T cells and altered the clinical symptoms of autoimmune inflammation in the eye. The ability to use retinal extract for the antigen raises the possibility that retinal extract could be used to produce autologous TolAPC and then used as therapy in human uveitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.